| Literature DB >> 31132177 |
L M Prens1, J Huizinga1, I C Janse2, B Horváth1.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic debilitating skin disease, frequently located in the groin and anogenital area, leading to a substantial impact on quality of life and sexual health in patients with HS. Skin-tissue-sparing excision with electrosurgical peeling (STEEP) is a procedure with known low recurrence rates and high patient satisfaction in retrospective series. However, a prospective study to investigate the impact of any major surgery on specific aspects of the quality of life has not yet been performed.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31132177 PMCID: PMC6852185 DOI: 10.1111/jdv.15706
Source DB: PubMed Journal: J Eur Acad Dermatol Venereol ISSN: 0926-9959 Impact factor: 6.166
Patient characteristics
|
| |
|---|---|
|
| 39.5 ± 11.1 |
|
| |
| Male (%) | 5 (13%) |
| Female (%) | 34 (87%) |
|
| 29.0 ± 5.5 |
|
| |
| Current or ex‐smoker | 30 (76.9%) |
|
| |
| IA | 2 (10.3%) |
| IB | 2 (10.3%) |
| IIA | 6 (15.4%) |
| IIB | 21 (53.8%) |
| IIC | 4 (10.3%) |
| III | 4 (10.3%) |
|
| 5 (13%) |
Frequencies surgical sites
| Surgical site |
|
|---|---|
| Armpit | 12 (30.8) |
| Groin | 22 (56.4) |
| Labia/scrotum | 2 (5.2) |
| Other | 3 (7.7) |
| Total | 39 (100) |
Surgical outcomes
|
| Mean wound surface (cm2) ± SD |
| Mean TTWC (days) ± SD |
| |
|---|---|---|---|---|---|
|
| 35 | 81.3 ± 48.9 | |||
|
| 38 | 74.0 ± 86.8 | 0.002 | ||
|
| |||||
| Yes | 4 | 118.8 ± 86.8 | 0.282 | 185 ± 25.4 | <0.0001 |
| No | 34 | 68.8 ± 86.4 | 67.9 ± 32.1 | ||
|
| |||||
| Yes | 26/24 | 67.9 ± 65.9 | 0.531 | 68.5 ± 34.4 | 0.070 |
| No | 12 | 87.3 ± 123.2 | 109.4 ± 64.5 | ||
|
| |||||
| I | 4/3 | 18.8 ± 14.4 | 0.046 | 34.7 ± 6.4 | 0.031 |
| II | 30/28 | 58.6 ± 53.9 | 0.072 | 75.8 ± 37.6 | 0.001 |
| III | 4 | 245 ± 138.2 | 155 ± 68.2 | ||
|
| 39 | 0.102 | |||
| ≤25 | 9/10 | 42.4 ± 62.1 | 0.216 | 68.6 ± 30.4 | 0.230 |
| >25 | 29/25 | 83.8 ± 91.8 | 86.4 ± 54.3 | ||
Number of patients with data available per outcome.
Regression analysis with outcome variable TTWC.
Independent samples t‐test.
Independent samples t‐test with Hurley I and Hurley II being compared with the Hurley III group.
Characteristics of patients with biologic treatment
| Patient ID | Gender | Age (years) | Body mass index kg/m2 | Current smoker (Yes/No) | Refined Hurley stage | Biologic regimen | Started before/after surgery | Number of treatment weeks before surgery | Treatment ongoing at end of study? (week 26) | Relapse (Yes/No) |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | F | 51 | 36.7 | No | III | Adalimumab 40 mg QW | Before | 14 | Yes | No |
| 9 | F | 34 | 28.7 | No | IIB | Adalimumab 40 mg QW | Before | 13 | Yes | No |
| 24 | M | 26 | 33.0 | Yes | III | Infliximab 500mg E6W | Before | 184 | Yes | No |
| 28 | F | 44 | 25.7 | Yes | IIB | Adalimumab 40 mg QW | Before | 221 | Yes | No |
| 39 | F | 50 | 32.2 | No | III | Adalimumab 40 mg QW | After | −7 | Yes | No |
Former smoker.
Smokes fruit tobacco.
Never smoked.
Estimation: no exact start date was reported.
Biologic treatment started 7 weeks after surgery.
Figure 1(a) Mean overall DLQI score. (b) Mean overall WPAI‐HS‐scores. *Significant increase in activity impairment at week 2 (P = 0.039). (c) Mean ASEX score.